ImmunArray Ltd. (IAL) is developing novel in-vitro diagnostic (IVD) tests, based on its iCHIP microarray technology platform. The products support a personalized medicine approach and IAL's first product family will provide tests for diagnosis, prognosis and therapeutic guidance of autoimmune diseases and for improving transplantation medicine.
Founded in 2006, ImmunArray Ltd. holds an exclusive, worldwide license from the Weizmann Institute of Science for the iCHIP technology, and has a strong IP portfolio covering its methodologies and applications. The company also has licenses from Brigham and Women’s Hospital and Johns Hopkins University for additional components of the technology. The company has assembled a distinguished group of world-renowned advisors and partners, and boasts a seasoned management team with a solid track record in launching early-stage biotechnology companies.
Visit www.immunarray.com for more information.